作者
Daniel J Brat, Kenneth Aldape, Howard Colman, Dominique Figrarella-Branger, Gregory N Fuller, Caterina Giannini, Eric C Holland, Robert B Jenkins, Bette Kleinschmidt-DeMasters, Takashi Komori, Johan M Kros, David N Louis, Catriona McLean, Arie Perry, Guido Reifenberger, Chitra Sarkar, Roger Stupp, Martin J van den Bent, Andreas von Deimling, Michael Weller
发表日期
2020/3
期刊
Acta neuropathologica
卷号
139
页码范围
603-608
出版商
Springer Berlin Heidelberg
简介
The diagnostic importance of IDH mutational status in diffuse gliomas was first formally recognized within the updated 4th edition of the WHO Classification of Tumours of the Central Nervous System (2016). Its introduction as a diagnostic marker was based on evidence that incorporation of biomarkers into an integrated diagnosis provided a more reproducible and clinically meaningful classification of diffuse gliomas in adults [20–22]. For IDH-mutant diffuse astrocytic gliomas, the integrated diagnostic entities (and corresponding grades) of the 2016 WHO Classification included diffuse astrocytoma,
学术搜索中的文章
DJ Brat, K Aldape, H Colman, D Figrarella-Branger… - Acta neuropathologica, 2020